Tyrosine kinase 2 inhibitors for plaque psoriasis: mechanisms of action and advances in clinical research
- VernacularTitle:酪氨酸激酶2抑制剂治疗斑块状银屑病的作用机制和临床研究进展
- Author:
Liyan YUAN
1
;
Xiaoling YU
1
;
Xiaohua WANG
1
;
Bin YANG
1
Author Information
- Publication Type:Journal Article
- Keywords: Psoriasis; Signal transduction; Janus kinases; TYK2 kinase; Deucravacitinib
- From: Chinese Journal of Dermatology 2025;58(11):1095-1098
- CountryChina
- Language:Chinese
- Abstract: With the deepening understanding of the pathogenesis of psoriasis, small-molecule drugs targeting the key Janus kinase (JAK) -tyrosine kinase (TYK) 2 pathway have gained increasing interest. TYK2-related pathways play an important role in the pathogenesis of psoriasis, while they are not involved in modulating broad biological effects, making them one of the potential therapeutic targets for the efficient and safe treatment of psoriasis. How to improve the selectivity and specificity of TYK2 inhibitors to minimize adverse reactions associated with the inhibition of other pathways has been one of the key directions for development of drugs targeting TYK2 in recent years. This review summarizes the role of TYK2 pathway in the pathogenesis of psoriasis, the modes of action of TYK2 inhibitors (competitive or allosteric inhibition), and the latest clinical research progress.
